A Cochrane review included 2 studies with a total of 514 subjects. Both trials recruited adults, the majority of whom had a partial onset to their seizures. Daily doses of 300 mg, 600 mg, 800 mg and 1200 mg of remacemide were tested vs. placebo. The overall relative risk (RR) for remacemide versus placebo with 95% CI for a 50 per cent or greater reduction in seizure frequency was 1.59 (95% CI 0.91 to 2.79). Regression models suggested a significant effect for 800-1200mg remacemide per day. Remacemide was more likely to be withdrawn than placebo, the RR for treatment withdrawal was 1.90 (95% CI 1.00 to 3.60). Dizziness was significantly associated with remacemide (RR 3.08, 99% CI 1.37 to 6.95). Effects on cognition and quality of life were not reported.